Literature DB >> 9594360

Determination of antibodies to extractable nuclear antigens by commercial kits: a multicenter study.

P Cordiali Fei1, G D'Agosto, F Ameglio, G Valesini, C Alessandri, A Farsi, M P Domenighetti, A Passaleva, F Scamardella, R Neri, S Bombardieri, M Quinzanini, F Franceschini, F Chiarotti.   

Abstract

Several enzyme immunoassays for serum antibodies to extractable nuclear antigen have recently become available. The aim of this study was to evaluate the results obtained with: (1) the same kit under different conditions; (2) different enzyme immunoassays; (3) Western blot and enzyme immunoassays. Twenty-five sera from patients with autoimmune disorders were tested in five different laboratories by one Western blot and four enzyme immunoassay commercial kits. The different methods produced comparable qualitative results. However, semiquantitative evaluation, based on a cut-off value (index), yielded different results due both to laboratory conditions and to the kits employed. Standardization of commercial products and methods should be improved so that the results of different laboratories can be compared and large-scale and follow-up studies conducted. Western blot analysis could also be useful to analyze complex reactivities, although greater experience is necessary to interpret these results correctly.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9594360     DOI: 10.1007/s005990050014

Source DB:  PubMed          Journal:  Int J Clin Lab Res        ISSN: 0940-5437


  2 in total

1.  Study of autoimmunity in Klinefelter's syndrome and idiopathic hypogonadotropic hypogonadism.

Authors:  Cagatay Oktenli; Zeki Yesilova; Ismail Hakki Kocar; Ugur Musabak; Metin Ozata; Ali Inal; Davut Gül; Yavuz Sanisoglu
Journal:  J Clin Immunol       Date:  2002-05       Impact factor: 8.317

Review 2.  The use and abuse of commercial kits used to detect autoantibodies.

Authors:  Marvin J Fritzler; Allan Wiik; Mark L Fritzler; Susan G Barr
Journal:  Arthritis Res Ther       Date:  2003-06-09       Impact factor: 5.156

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.